Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Atricure Inc's Business Segments
Atricure Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 154
Regions Reported
3
Revenue Share by Region -
- Europe11.2%
- Asia Pacific5.6%
- Other International1.4%
Revenue by Geographic Region -
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 17 | 11.2% |
| Asia Pacific | $ 9 | 5.6% |
| Other International | $ 2 | 1.4% |
Revenue by Product & Service Category -
- Appendage Management33.6%
- Openheart26.6%
- Pain Management17.6%
- Minimally Invasive3.9%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Appendage Management | $ 52 | 33.6% |
| Openheart | $ 41 | 26.6% |
| Pain Management | $ 27 | 17.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Atricure Inc dataset.
Description of Atricure Inc
Atricure Inc is a leading medical technology company that specializes in the development and commercialization of innovative devices that help surgeons around the world to perform better cardiac surgery procedures. The company's main focus is on the provision of advanced and minimally invasive surgical solutions that enhance patient outcomes and reduce healthcare costs.
Atricure was founded in 2000, and since then, it has become an industry leader in the field of electrophysiology, with a particular focus on the treatment of atrial fibrillation (AF). The company is headquartered in Mason, OH, and has a team of over 900 employees worldwide, including in Europe, Asia, and the Americas.
Atricure's product portfolio includes a range of advanced surgical devices and instruments that are used to treat various cardiac conditions. Some of the company's key products include the AtriCure CryoICE Cryoablation System, the AtriClip Left Atrial Appendage Management System, and the EPi-Sense Coagulation System.
The AtriCure CryoICE Cryoablation System is a minimally invasive system that delivers cold energy to the heart tissue to create a controlled lesion, which stops the abnormal electrical signals that can cause AF. The AtriClip Left Atrial Appendage Management System is designed to exclude the left atrial appendage from the circulation, reducing the risk of stroke in patients with AF.
The EPi-Sense Coagulation System is a bipolar radiofrequency energy device that helps surgeons safely create critically important lines of conduction block in the heart, which can help treat a range of cardiac abnormalities including AF.
Atricure is committed to innovation and product development, maintaining partnerships with leading researchers and medical institutions, and investing significant amounts in R&D every year. The company's culture is rooted in collaboration, integrity, passion, and excellence, and it places a significant emphasis on investing in employee development, diversity, and inclusion.
In conclusion, Atricure Inc is a leading medical technology company that has been at the forefront of innovation in the field of cardiac surgery. With a robust product portfolio, a strong commitment to R&D, and a culture of excellence, the company is well-positioned to achieve sustained growth and remain an industry leader in the years to come.
Atricure was founded in 2000, and since then, it has become an industry leader in the field of electrophysiology, with a particular focus on the treatment of atrial fibrillation (AF). The company is headquartered in Mason, OH, and has a team of over 900 employees worldwide, including in Europe, Asia, and the Americas.
Atricure's product portfolio includes a range of advanced surgical devices and instruments that are used to treat various cardiac conditions. Some of the company's key products include the AtriCure CryoICE Cryoablation System, the AtriClip Left Atrial Appendage Management System, and the EPi-Sense Coagulation System.
The AtriCure CryoICE Cryoablation System is a minimally invasive system that delivers cold energy to the heart tissue to create a controlled lesion, which stops the abnormal electrical signals that can cause AF. The AtriClip Left Atrial Appendage Management System is designed to exclude the left atrial appendage from the circulation, reducing the risk of stroke in patients with AF.
The EPi-Sense Coagulation System is a bipolar radiofrequency energy device that helps surgeons safely create critically important lines of conduction block in the heart, which can help treat a range of cardiac abnormalities including AF.
Atricure is committed to innovation and product development, maintaining partnerships with leading researchers and medical institutions, and investing significant amounts in R&D every year. The company's culture is rooted in collaboration, integrity, passion, and excellence, and it places a significant emphasis on investing in employee development, diversity, and inclusion.
In conclusion, Atricure Inc is a leading medical technology company that has been at the forefront of innovation in the field of cardiac surgery. With a robust product portfolio, a strong commitment to R&D, and a culture of excellence, the company is well-positioned to achieve sustained growth and remain an industry leader in the years to come.
AtriCure Inc. a prominent player in the medical device industry, specializes in the development and manufacturing of innovative therapies and devices specifically targeting atrial fibrillation (AFib). This condition, characterized by irregular heartbeats, poses significant risks such as stroke and heart failure. AtriCure is at the forefront of addressing these challenges through various segments, products, and services designed to enhance patient outcomes and streamline surgical processes.
Segments
1. Open-Heart Surgery (OHS)
AtriCure offers a range of cutting-edge devices tailored for use during open-heart surgical procedures aimed at treating atrial fibrillation. These devices assist surgeons in isolating the pulmonary veins, creating targeted lesions, and performing other critical surgical interventions to restore normal heart rhythm. The innovation in this segment focuses on tools that enhance precision and effectiveness while minimizing potential complications during surgeries.
2. Minimally Invasive Surgery (MIS)
Recognizing the trend towards less invasive surgical techniques, AtriCure provides an array of MIS devices for AFib treatment. These devices are engineered to facilitate procedures that involve smaller incisions, leading to reduced trauma, shorter recovery times, and less post-operative pain for patients. Key offerings in this segment include technologies that utilize radiofrequency ablation (RFA) and cryoablation, as well as epicardial access systems designed for minimally invasive interventions.
Products
1. AtriClip
The AtriClip is AtriCures flagship product and a pioneering device designed to occlude and isolate the left atrial appendage (LAA). By effectively sealing off the LAA, the AtriClip plays a crucial role in preventing the formation of blood clots, thereby reducing the risk of stroke in patients with AFib. This device can be utilized during traditional cardiac surgeries or through a minimally invasive approach, showcasing its versatility in clinical settings.
2. Isolator Synergy
The Isolator Synergy ablation system represents an advanced solution used prominently during open-heart surgery. It is specifically engineered to treat cardiac arrhythmias, with a focus on atrial fibrillation. This system works in conjunction with AtriCures other devices to facilitate the creation of precise lesions within the hearts tissue, leading to effective ablation and enhanced patient outcomes.
3. CryoICE
The CryoICE device employs sophisticated cryoablation technology that utilizes extreme cold to freeze and ablate diseased cardiac tissue. This method is effective in creating precise lesions, thereby disrupting the abnormal electrical pathways that contribute to AFib. The CryoICE system is an important tool in the arsenal of minimally invasive AFib treatment options.
4. EPi-Sense
EPi-Sense is a notable innovative technology that allows surgeons to access the outer layer of the heart via small incisions made in the chest. Utilizing advanced imaging techniques and robotic arms, this device aids in suturing the epicardium and establishing lesions to mitigate the electrical disturbances leading to AFib. The precision offered by EPi-Sense enhances the surgeons ability to effectively treat AFib in a minimally invasive manner.
Services
1. Clinical Research
AtriCure places a strong emphasis on clinical research and development to continually advance its therapeutic offerings. The company actively collaborates with healthcare professionals and research institutions to conduct clinical trials aimed at assessing the safety and efficacy of their products. This commitment not only fosters innovation but also ensures that their therapies are grounded in scientific rigor.
2. Training and Education
AtriCure understands that the effective deployment of its products relies on the expertise of healthcare providers. To this end, the company offers comprehensive training and education programs tailored for surgeons, nurses, and other medical professionals. These programs encompass advanced surgical techniques and the proper use of AtriCures technologies, ensuring that healthcare providers are well-equipped to deliver optimal patient care.
3. Technical Support
To bolster the confidence of healthcare providers utilizing their devices, AtriCure provides robust technical support services. This includes ongoing technical assistance, equipment servicing, and repair solutions, all aimed at ensuring the longevity and optimal performance of their medical devices. The company’s commitment to technical support underscores its dedication to enhancing the overall efficiency of healthcare delivery in the context of AFib treatment.
Conclusion
In summary, AtriCure Inc. is an innovator in the medical device landscape, offering an array of advanced solutions for the treatment of atrial fibrillation through both open-heart and minimally invasive surgical approaches. Their diverse portfolio of products, including the AtriClip and CryoICE, alongside their dedication to clinical research, training, and technical support, positions AtriCure as a leader in improving clinical outcomes for patients suffering from AFib. The company remains steadfast in its mission to enhance the quality of life for patients through revolutionary therapies and technologies.
,
Segments
1. Open-Heart Surgery (OHS)
AtriCure offers a range of cutting-edge devices tailored for use during open-heart surgical procedures aimed at treating atrial fibrillation. These devices assist surgeons in isolating the pulmonary veins, creating targeted lesions, and performing other critical surgical interventions to restore normal heart rhythm. The innovation in this segment focuses on tools that enhance precision and effectiveness while minimizing potential complications during surgeries.
2. Minimally Invasive Surgery (MIS)
Recognizing the trend towards less invasive surgical techniques, AtriCure provides an array of MIS devices for AFib treatment. These devices are engineered to facilitate procedures that involve smaller incisions, leading to reduced trauma, shorter recovery times, and less post-operative pain for patients. Key offerings in this segment include technologies that utilize radiofrequency ablation (RFA) and cryoablation, as well as epicardial access systems designed for minimally invasive interventions.
Products
1. AtriClip
The AtriClip is AtriCures flagship product and a pioneering device designed to occlude and isolate the left atrial appendage (LAA). By effectively sealing off the LAA, the AtriClip plays a crucial role in preventing the formation of blood clots, thereby reducing the risk of stroke in patients with AFib. This device can be utilized during traditional cardiac surgeries or through a minimally invasive approach, showcasing its versatility in clinical settings.
2. Isolator Synergy
The Isolator Synergy ablation system represents an advanced solution used prominently during open-heart surgery. It is specifically engineered to treat cardiac arrhythmias, with a focus on atrial fibrillation. This system works in conjunction with AtriCures other devices to facilitate the creation of precise lesions within the hearts tissue, leading to effective ablation and enhanced patient outcomes.
3. CryoICE
The CryoICE device employs sophisticated cryoablation technology that utilizes extreme cold to freeze and ablate diseased cardiac tissue. This method is effective in creating precise lesions, thereby disrupting the abnormal electrical pathways that contribute to AFib. The CryoICE system is an important tool in the arsenal of minimally invasive AFib treatment options.
4. EPi-Sense
EPi-Sense is a notable innovative technology that allows surgeons to access the outer layer of the heart via small incisions made in the chest. Utilizing advanced imaging techniques and robotic arms, this device aids in suturing the epicardium and establishing lesions to mitigate the electrical disturbances leading to AFib. The precision offered by EPi-Sense enhances the surgeons ability to effectively treat AFib in a minimally invasive manner.
Services
1. Clinical Research
AtriCure places a strong emphasis on clinical research and development to continually advance its therapeutic offerings. The company actively collaborates with healthcare professionals and research institutions to conduct clinical trials aimed at assessing the safety and efficacy of their products. This commitment not only fosters innovation but also ensures that their therapies are grounded in scientific rigor.
2. Training and Education
AtriCure understands that the effective deployment of its products relies on the expertise of healthcare providers. To this end, the company offers comprehensive training and education programs tailored for surgeons, nurses, and other medical professionals. These programs encompass advanced surgical techniques and the proper use of AtriCures technologies, ensuring that healthcare providers are well-equipped to deliver optimal patient care.
3. Technical Support
To bolster the confidence of healthcare providers utilizing their devices, AtriCure provides robust technical support services. This includes ongoing technical assistance, equipment servicing, and repair solutions, all aimed at ensuring the longevity and optimal performance of their medical devices. The company’s commitment to technical support underscores its dedication to enhancing the overall efficiency of healthcare delivery in the context of AFib treatment.
Conclusion
In summary, AtriCure Inc. is an innovator in the medical device landscape, offering an array of advanced solutions for the treatment of atrial fibrillation through both open-heart and minimally invasive surgical approaches. Their diverse portfolio of products, including the AtriClip and CryoICE, alongside their dedication to clinical research, training, and technical support, positions AtriCure as a leader in improving clinical outcomes for patients suffering from AFib. The company remains steadfast in its mission to enhance the quality of life for patients through revolutionary therapies and technologies.
,